Notably, muscle cramps are not prominently featured among the listed adverse reactions in FDA labeling, leading many patients and clinicians to question whether there is a genuine association between GLP-1 therapy and musculoskeletal symptoms
Filip Krag Knop has served on scientific advisory panels and/or been part of speakers bureaus for, served as a consultant to, and/or received research support from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi, and Zealand Pharma
(2007) Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways
For tirzepatide, the prescribing information does not specify a preconception interval but advises discontinuation when pregnancy is recognized